Opus Genetics Secures FDA Nod for Presbyopia Treatment, Expanding Ophthalmic Portfolio

  • FDA approved Opus Genetics' phentolamine ophthalmic solution 0.75% for presbyopia treatment on October 16, 2026.
  • Approval triggered by positive Phase 3 VEGA-2 and VEGA-3 trial results, meeting all primary and secondary endpoints.
  • Opus Genetics and Viatris Inc. hold a global licensing agreement for commercialization in the U.S.
  • Presbyopia affects ~90% of U.S. adults over 45, creating a substantial market opportunity.

This FDA approval marks Opus Genetics' second U.S. drug approval, reinforcing its clinical and regulatory capabilities. The expansion into presbyopia treatment positions the company to tap into a large, underserved market, while its gene therapy pipeline for inherited retinal diseases (IRDs) underscores a long-term strategic focus on vision restoration. The partnership with Viatris Inc. suggests a balanced approach to leveraging external commercial expertise while maintaining internal innovation.

Commercial Execution
How Opus Genetics and Viatris will collaborate to capture market share in the presbyopia treatment space.
Pipeline Progress
The pace at which Opus Genetics advances its gene therapy pipeline for inherited retinal diseases.
Regulatory Strategy
Whether Opus Genetics can leverage this approval to secure additional indications or expand into new markets.